BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014;11:81-90. [PMID: 24281059 DOI: 10.1038/nrclinonc.2013.218] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 11.6] [Reference Citation Analysis]
Number Citing Articles
1 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
2 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
3 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
4 Ohwada S, Morita S. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial. Pharmaceut Statist 2016;15:420-9. [DOI: 10.1002/pst.1761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
6 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
7 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
8 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
9 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
10 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
11 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
12 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
13 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
14 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
15 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
16 Korn EL, Freidlin B. Quantitative assessment of a prognostic or predictive biomarker panel. J Biopharm Stat 2018;28:264-81. [PMID: 29083961 DOI: 10.1080/10543406.2017.1378665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Vojdani S, Ghaderian SMH, Zali A, Rakhshan A, Oraee Yazdani S, Poursheikhani A, Bidari Zerehpoush F, Sharifi G. Altered expression of EGFR and miR-34a derived from serum and tumoral tissue was associated with glioblastoma multiform. Exp Mol Pathol 2021;121:104655. [PMID: 34062187 DOI: 10.1016/j.yexmp.2021.104655] [Reference Citation Analysis]
18 Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH. Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. J Immunother 2015;38:259-66. [PMID: 26261889 DOI: 10.1097/CJI.0000000000000089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Sugitani T, Posch M, Bretz F, Koenig F. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. Stat Med 2018;37:3387-402. [PMID: 29945304 DOI: 10.1002/sim.7851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Shin SW, Lee BS, Yang K, Amornkitbamrung L, Jang MS, Ku BM, Cho SW, Lee JH, Bae H, Oh BK, Ahn MJ, Lim YT, Um SH. Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ. Sci Rep 2017;7:13499. [PMID: 29044199 DOI: 10.1038/s41598-017-13456-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
22 Zhao W, Ma W, Wang F, Hu F. Incorporating covariates information in adaptive clinical trials for precision medicine. Pharm Stat 2021. [PMID: 34369053 DOI: 10.1002/pst.2160] [Reference Citation Analysis]
23 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
25 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
26 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
27 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
28 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
29 Bhattacharyya A, Rai SN. Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design. Contemp Clin Trials Commun 2019;15:100378. [PMID: 31289760 DOI: 10.1016/j.conctc.2019.100378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
31 Meyer NJ, Reilly JP, Anderson BJ, Palakshappa JA, Jones TK, Dunn TG, Shashaty MGS, Feng R, Christie JD, Opal SM. Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration. Crit Care Med 2018;46:21-8. [PMID: 28991823 DOI: 10.1097/CCM.0000000000002749] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
32 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
33 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
34 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
35 Stringer KA, McKay RT, Karnovsky A, Quémerais B, Lacy P. Metabolomics and Its Application to Acute Lung Diseases. Front Immunol 2016;7:44. [PMID: 26973643 DOI: 10.3389/fimmu.2016.00044] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
36 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
37 Turtle L, Bhalla N, Willett A, Biggar R, Leadbetter J, Georgiou G, Wilson JM, Vivekanandan S, Hawkins MA, Brada M, Fenwick JD. Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol 2021;16:95. [PMID: 34082782 DOI: 10.1186/s13014-021-01824-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
39 Meyer NJ, Calfee CS. Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. Lancet Respir Med 2017;5:512-23. [PMID: 28664850 DOI: 10.1016/S2213-2600(17)30187-X] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
40 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
41 Tanniou J, van der Tweel I, Teerenstra S, Roes KC. Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes. BMC Med Res Methodol 2016;16:20. [PMID: 26891992 DOI: 10.1186/s12874-016-0122-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
42 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
43 Wang T, Wang X, Zhou H, Cai J, George SL. Auxiliary variable-enriched biomarker-stratified design. Stat Med 2018;37:4610-35. [PMID: 30221368 DOI: 10.1002/sim.7938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
45 Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M. Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. Clin Neuropathol 2015;34:250-7. [PMID: 26295302 DOI: 10.5414/np300904] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
46 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
47 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
48 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
49 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
50 Menis J, Litière S, Tryfonidis K, Golfinopoulos V. The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med 2016;4:267. [PMID: 27563654 DOI: 10.21037/atm.2016.06.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
51 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
52 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
53 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
54 Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, Goldberg A, Karpinski M, Shaw J, Rush DN, Nickerson PW. HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant 2019;19:1708-19. [PMID: 30414349 DOI: 10.1111/ajt.15177] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
55 Tohkin M, Saito Y, Yagi S, Asano K, Maekawa K, Osabe M, Iida S, Miyata N. Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documents. Drug Metab Pharmacokinet 2020;35:187-90. [PMID: 32007355 DOI: 10.1016/j.dmpk.2020.01.003] [Reference Citation Analysis]
56 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
57 Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther 2021;228:107932. [PMID: 34174272 DOI: 10.1016/j.pharmthera.2021.107932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Korn EL, Freidlin B. Reader reaction on estimation of treatment effects in all-comers randomized clinical trials with a predictive marker. Biometrics 2017;73:706-8. [PMID: 27775815 DOI: 10.1111/biom.12592] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
60 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
61 Michiels S, Ternès N, Rotolo F. Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Ann Oncol 2016;27:2160-7. [PMID: 27634691 DOI: 10.1093/annonc/mdw307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
62 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
63 Freidlin B, Korn EL. A Problematic Biomarker Trial Design. J Natl Cancer Inst 2021:djab144. [PMID: 34289052 DOI: 10.1093/jnci/djab144] [Reference Citation Analysis]
64 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
65 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
66 Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res 2016;5:39-50. [PMID: 26958492 DOI: 10.3978/j.issn.2218-6751.2016.01.03] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
67 Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J. Finding useful biomarkers for Parkinson's disease. Sci Transl Med 2018;10:eaam6003. [PMID: 30111645 DOI: 10.1126/scitranslmed.aam6003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
68 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
69 Hall JA, Salgado R, Lively T, Sweep F, Schuh A. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. The Lancet Oncology 2014;15:e184-93. [DOI: 10.1016/s1470-2045(13)70607-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
70 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
71 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
72 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
73 Tsourounis M, Stuart J, Pignato W, Toscani M, Barone J. Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics. Ther Innov Regul Sci 2015;49:530-43. [PMID: 30222427 DOI: 10.1177/2168479015570330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
74 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
75 Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, Siegel R, Fink M, Ahmed S, Millholland J, Schuhmacher A, Hinder M, Piali L, Roth A. Translational precision medicine: an industry perspective. J Transl Med 2021;19:245. [PMID: 34090480 DOI: 10.1186/s12967-021-02910-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
77 Huang SW, Ali ND, Zhong L, Shi J. MicroRNAs as biomarkers for human glioblastoma: progress and potential. Acta Pharmacol Sin 2018;39:1405-13. [PMID: 29417946 DOI: 10.1038/aps.2017.173] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
78 Goldberg RM. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? Oncologist 2015;20:1448-56. [PMID: 26512044 DOI: 10.1634/theoncologist.2015-0263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
79 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
80 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
81 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
82 Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol 2015;11:556-66. [PMID: 26369507 DOI: 10.1038/nrneurol.2015.171] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 13.3] [Reference Citation Analysis]
83 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
84 Yang J, Jia L, Li Y, Qiu Q, Quan M, Jia J. Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. J Alzheimers Dis 2021;81:19-32. [PMID: 33749646 DOI: 10.3233/JAD-201068] [Reference Citation Analysis]
85 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. J Natl Cancer Inst 2017;109. [PMID: 28376148 DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
86 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
87 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
88 Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017;28:34-43. [PMID: 28177494 DOI: 10.1093/annonc/mdw413] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 32.5] [Reference Citation Analysis]
89 Kraus VB, Blanco FJ, Englund M, Henrotin Y, Lohmander LS, Losina E, Önnerfjord P, Persiani S. OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 2015;23:686-97. [PMID: 25952342 DOI: 10.1016/j.joca.2015.03.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
90 Goligher EC, Combes A, Brodie D, Ferguson ND, Pesenti AM, Ranieri VM, Slutsky AS; SUPERNOVA investigators (European Society of Intensive Care Medicine trials group)  and for the International ECMO Network (ECMONet). Determinants of the effect of extracorporeal carbon dioxide removal in the SUPERNOVA trial: implications for trial design. Intensive Care Med 2019;45:1219-30. [PMID: 31432216 DOI: 10.1007/s00134-019-05708-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
91 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
92 Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 2021;9:e002459. [PMID: 34215688 DOI: 10.1136/jitc-2021-002459] [Reference Citation Analysis]
93 Sweatt AJ, Reddy R, Rahaghi FN, Al-Naamani N; American Thoracic Society Pulmonary Circulation Assembly Early Career Working Group. What's new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference. Pulm Circ 2021;11:20458940211040713. [PMID: 34471517 DOI: 10.1177/20458940211040713] [Reference Citation Analysis]
94 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
95 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
96 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
97 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
98 Ramaiah SK, Walker DB. Regulatory Forum Opinion Piece*: Veterinary Pathologists in Translational Pharmacology and Biomarker Integration in Drug Discovery and Development. Toxicol Pathol 2016;44:137-46. [PMID: 26839329 DOI: 10.1177/0192623315620051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH Jr, Welch JJ, Korn EL, Ullmann CD, Hirsch FR. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. J Thorac Oncol 2014;9:1443-8. [PMID: 25521397 DOI: 10.1097/JTO.0000000000000314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
100 Sánchez NS, Mills GB, Mills Shaw KR. Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 2017;18:1525-39. [PMID: 29061079 DOI: 10.2217/pgs-2017-0094] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
101 Freidlin B, Allegra CJ, Korn EL. Moving Molecular Profiling to Routine Clinical Practice: A Way Forward? J Natl Cancer Inst 2020;112:773-8. [PMID: 31868907 DOI: 10.1093/jnci/djz240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Yang B, Zhou Y, Zhang L, Cui L. Enrichment design with patient population augmentation. Contemp Clin Trials 2015;42:60-7. [PMID: 25746817 DOI: 10.1016/j.cct.2015.02.010] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
103 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
104 Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers Med 2017;7:E1. [PMID: 28125057 DOI: 10.3390/jpm7010001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
105 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
106 Anderson BJ, Calfee CS, Liu KD, Reilly JP, Kangelaris KN, Shashaty MGS, Lazaar AL, Bayliffe AI, Gallop RJ, Miano TA, Dunn TG, Johansson E, Abbott J, Jauregui A, Deiss T, Vessel K, Belzer A, Zhuo H, Matthay MA, Meyer NJ, Christie JD. Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study. Crit Care 2019;23:400. [PMID: 31818332 DOI: 10.1186/s13054-019-2684-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
107 Campbell J, King NB. “Unsettling circularity”: Clinical trial enrichment and the evidentiary politics of chronic pain. BioSocieties 2017;12:191-216. [DOI: 10.1057/biosoc.2016.7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
108 Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J Pers Med 2017;7:E19. [PMID: 29207572 DOI: 10.3390/jpm7040019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
109 Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. Int J Biol Markers 2015;30:e252-3. [PMID: 25684439 DOI: 10.5301/jbm.5000136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
110 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
111 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
112 Nandal S, Burt T. Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. Int J Mol Sci 2017;18:E448. [PMID: 28218733 DOI: 10.3390/ijms18020448] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
113 Belitskaya-lévy I, Wang H, Shih M, Tian L, Doros G, Lew RA, Lu Y. A New Overall-Subgroup Simultaneous Test for Optimal Inference in Biomarker-Targeted Confirmatory Trials. Stat Biosci 2018;10:297-323. [DOI: 10.1007/s12561-016-9174-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
115 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
116 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
117 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
118 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
119 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
120 Hu C, Dignam JJ. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precis Oncol 2019;3:PO. [PMID: 32923854 DOI: 10.1200/PO.19.00086] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
121 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
122 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
123 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
124 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
125 Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordbar DD, Saenger YM. Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. Hematol Oncol Clin North Am 2019;33:291-9. [PMID: 30833001 DOI: 10.1016/j.hoc.2018.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
126 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
127 Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02611-0. [PMID: 34363901 DOI: 10.1016/j.ijrobp.2021.07.1700] [Reference Citation Analysis]
128 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
129 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
130 Kunos CA, Howells R, Chauhan A, Myint ZW, Bernard ME, El Khouli R, Capala J. Radiopharmaceutical Validation for Clinical Use. Front Oncol 2021;11:630827. [PMID: 33747951 DOI: 10.3389/fonc.2021.630827] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
132 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
133 Bakouny Z, Choueiri TK. IL-8 and cancer prognosis on immunotherapy. Nat Med 2020;26:650-1. [PMID: 32405061 DOI: 10.1038/s41591-020-0873-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
134 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
135 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
136 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
137 Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther 2021:S2666-6367(21)00946-5. [PMID: 34107340 DOI: 10.1016/j.jtct.2021.05.027] [Reference Citation Analysis]
138 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
139 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. J Natl Cancer Inst 2017;109. [PMID: 28376148 DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
140 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
141 Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials 2021;100:106216. [PMID: 33246098 DOI: 10.1016/j.cct.2020.106216] [Reference Citation Analysis]
142 Korn EL, Othus M, Chen T, Freidlin B. Assessing treatment efficacy in the subset of responders in a randomized clinical trial. Ann Oncol 2017;28:1640-7. [PMID: 28444115 DOI: 10.1093/annonc/mdx197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
143 Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M. Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis (Edinb) 2018;109:61-8. [PMID: 29559122 DOI: 10.1016/j.tube.2017.11.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
144 Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res 2017;23:4970-9. [PMID: 28864725 DOI: 10.1158/1078-0432.CCR-16-3063] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
145 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
146 Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials 2015;16:430. [PMID: 26416387 DOI: 10.1186/s13063-015-0958-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
147 Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev 2016;43:74-82. [PMID: 26827695 DOI: 10.1016/j.ctrv.2015.12.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
148 Graf AC, Posch M, Koenig F. Adaptive designs for subpopulation analysis optimizing utility functions. Biom J 2015;57:76-89. [PMID: 25399844 DOI: 10.1002/bimj.201300257] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
149 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
150 Jang HJ, Lee A, Kang J, Song IH, Lee SH. Prediction of genetic alterations from gastric cancer histopathology images using a fully automated deep learning approach. World J Gastroenterol 2021; 27(44): 7687-7704 [PMID: 34908807 DOI: 10.3748/wjg.v27.i44.7687] [Reference Citation Analysis]
151 Catenacci DV. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967-996. [PMID: 25557400 DOI: 10.1016/j.molonc.2014.09.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
152 Sweatt AJ, Miyagawa K, Rhodes CJ, Taylor S, Del Rosario PA, Hsi A, Haddad F, Spiekerkoetter E, Bental-Roof M, Bland RD, Swietlik EM, Gräf S, Wilkins MR, Morrell NW, Nicolls MR, Rabinovitch M, Zamanian RT. Severe Pulmonary Arterial Hypertension is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. Chest 2021:S0012-3692(21)01255-1. [PMID: 34181952 DOI: 10.1016/j.chest.2021.06.028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One 2016;11:e0149803. [PMID: 26910238 DOI: 10.1371/journal.pone.0149803] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
154 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
155 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
156 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
157 Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39. [PMID: 31201092 DOI: 10.1016/j.jcyt.2019.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
158 Gilson C, Chowdhury S, Parmar MKB, Sydes MR; STAMPEDE Investigators. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clin Oncol (R Coll Radiol) 2017;29:778-86. [PMID: 29079227 DOI: 10.1016/j.clon.2017.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
159 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
160 Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
161 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
162 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
163 Mehra N, Lorente D, de Bono JS. What have we learned from exceptional tumour responses?: review and perspectives. Current Opinion in Oncology 2015;27:267-75. [DOI: 10.1097/cco.0000000000000182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
164 Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. Contemp Clin Trials Commun 2018;12:1-8. [PMID: 30182068 DOI: 10.1016/j.conctc.2018.08.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
165 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
166 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
167 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
168 Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G. Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clin Pharmacol Ther 2019;106:148-63. [PMID: 30107040 DOI: 10.1002/cpt.1211] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
169 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
170 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. J Natl Cancer Inst 2017;109. [PMID: 28376148 DOI: 10.1093/jnci/djx013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
171 Nonaka T, Igeta M, Matsui S. Statistical testing strategies for assessing treatment efficacy and marker accuracy in phase III trials. Pharm Stat 2019;18:459-75. [PMID: 30838777 DOI: 10.1002/pst.1937] [Reference Citation Analysis]
172 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
173 Oh J, Yi S, Gu N, Shin D, Yu KS, Yoon SH, Cho JY, Jang IJ. Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity. Genomics Inform 2018;16:52-8. [PMID: 30309203 DOI: 10.5808/GI.2018.16.3.52] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
174 Chitwood JR, Chakraborty N, Hammamieh R, Moe SM, Chen NX, Kacena MA, Natoli RM. Predicting fracture healing with blood biomarkers: the potential to assess patient risk of fracture nonunion. Biomarkers 2021;26:703-17. [PMID: 34555995 DOI: 10.1080/1354750X.2021.1985171] [Reference Citation Analysis]
175 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
176 Annunziata CM, Kohn EC. Clinical trials in gynecologic oncology: Past, present, and future. Gynecol Oncol 2018;148:393-402. [PMID: 29212614 DOI: 10.1016/j.ygyno.2017.11.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
177 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
178 Tarvin KA, Sandusky GE. Using molecular profiled human tissue to accelerate drug discovery. Expert Opin Drug Discov 2014;9:1383-7. [PMID: 25217252 DOI: 10.1517/17460441.2014.959926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 2015;33:1000-7. [PMID: 25667274 DOI: 10.1200/JCO.2014.58.2007] [Cited by in Crossref: 156] [Cited by in F6Publishing: 77] [Article Influence: 22.3] [Reference Citation Analysis]
180 Thiruthaneeswaran N, Bibby BAS, Yang L, Hoskin PJ, Bristow RG, Choudhury A, West C. Lost in application: Measuring hypoxia for radiotherapy optimisation. Eur J Cancer 2021;148:260-76. [PMID: 33756422 DOI: 10.1016/j.ejca.2021.01.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Pregelj L, Hwang TJ, Hine DC, Siegel EB, Barnard RT, Darrow JJ, Kesselheim AS. Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. Health Affairs 2018;37:724-31. [DOI: 10.1377/hlthaff.2017.1580] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
182 Sousa AR, Oliveira MJ, Sarmento B. Impact of CEA-targeting Nanoparticles for Drug Delivery in Colorectal Cancer. J Pharmacol Exp Ther 2019;370:657-70. [PMID: 30670480 DOI: 10.1124/jpet.118.254441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
183 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
184 Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx013] [Reference Citation Analysis]
185 Polley MC, Korn EL, Freidlin B. Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation. JCO Precis Oncol 2019;3:PO. [PMID: 32923845 DOI: 10.1200/PO.18.00416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]